A pilot feasibility study to evaluate the efficacy of ZD1839 [gefitinib] (Iressa) in eliminating chemo- and hormone- resistant cytokeratin-positive tumour cells circulating in the blood of women with breast cancer

Trial Profile

A pilot feasibility study to evaluate the efficacy of ZD1839 [gefitinib] (Iressa) in eliminating chemo- and hormone- resistant cytokeratin-positive tumour cells circulating in the blood of women with breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2008 Actual patient number is now 24 as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top